Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized total neoadjuvant therapy trial for MRI-defined intermediate/high-risk rectal cancer with organ preservation strategy
2024-511577-29-01Phase 3Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid and capecitabine in rectal adenocarcinoma (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Organ preservation. Planned start Mar 2020; status: authorised.
02
Drugs
oxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-511577-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511577-29-01.